In the lawsuit, AG Gentner Drummond outlined 200 individual prescription claims that were reimbursed below acquisition cost to 15 Oklahoma pharmacies.

Evercore ISI has updated its outlook on CVS Health (NYSE:CVS) shares, raising the price target from $60.00 to $65.00 while maintaining an Outperform rating. The adjustment comes in anticipation of future performance dynamics,

Leerink Partners maintained a Market Perform rating on CVS Health (NYSE:CVS) shares while increasing the price target from $51.00 to $55.00. The adjustment reflects the firm's expectation of an earnings recovery despite ongoing challenges within the Health Care Benefits (HCB) sector.

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without many pharmacy options.

Attorney General Gentner Drummond sued CVS Caremark Tuesday in an Oklahoma administrative court alleging that the company is under reimbursing pharmacies for prescription drugs.

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. During the quarter,

CVS Health's poor 2024 performance was driven by ... PBMs and MA plans are core to the CVS Caremark and Aetna insurance segments. But will the rhetoric stick? PBMs are an easy target.

The Health Care Benefits segment includes Aetna and other health insurance businesses. CVS acquired Aetna in 2017. In 2023, CVS's Health Care Benefits segment operates as one of the largest diversified health care benefits providers, serving more than 35 million people. This segment accounts for approximately 30% of the consolidated revenue.

Attorney General Gentner Drummond sued CVS Caremark Tuesday in an Oklahoma administrative court alleging that the company is under reimbursing pharmacies for prescription drugs. The lawsuit alleges CVS Caremark reimbursed Oklahoma pharmacies below the actual cost to acquire the drugs about 200 times between May and October 2024.

Attorney General Gentner Drummond sued CVS Caremark Tuesday in an Oklahoma administrative court alleging that the company is under reimbursing pharmacies for prescription drugs.